Illumina has acquired Fluent BioSciences to support its preparations for single-cell research. The acquisition was closed on July 9, 2024. Financial details of the transaction were not disclosed.
Post-acquisition, Illumina plans to improve its sequencing and informatics solutions by integrating Fluent's PIPseq V into its product portfolio to develop full end-to-end solutions for single-cell analysis. The company also plans to continue its existing partnerships in single-cell research by providing an open NGS platform that allows researchers to choose the tools suitable for their needs.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.